Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Neutral ...

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its ...

What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler analysts upgraded the stock's rating from Neutral to Buy. The ...

Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...

Piper Sandler upgraded Myriad Genetics (MYGN) to Overweight from Neutral with a price target of $12.50, up from $11.50. The stock is down more ...

Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.

UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad ...

Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (LSE:0K3W) from Neutral to Overweight. As of March 4, 2025, the average one-year price target for ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 7.1% year on year to $210.6 million. The company’s full-year ...

Myriad Genetics is down 21.1% since the beginning of the year, and at $10.65 per share, it is trading 62.8% below its 52-week high of $28.60 from September 2024.

Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Neutral to Overweight. As of March 4, 2025, the average one-year price target ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported a tough quarter(Q4 2024), with revenue missing expectations and 2025 ...